Dysregulation of IL6/IL6R-STAT3-SOCS3 signaling pathway in IBD-associated colorectal dysplastic lesions as compared to sporadic colorectal adenomas in non-IBD patients

被引:12
|
作者
Gui, Xianyong [1 ,2 ]
Iacucci, Marietta [3 ,4 ,5 ]
Ghosh, Subrata [3 ,4 ,5 ]
机构
[1] Univ Washington, Sch Med, Dept Lab Med & Pathol, Seattle, WA USA
[2] Univ Calgary, Cummings Sch Med, Dept Pathol & Lab Med, Calgary, AB, Canada
[3] Univ Calgary, Div Gastroenterol, Cummings Sch Med, Calgary, AB, Canada
[4] Univ Birmingham, Inst Translat Med, NIHR Biomed Res Ctr, Birmingham, W Midlands, England
[5] Univ Birmingham, NIHR Wellcome Trust Clin Res Facil, Birmingham, W Midlands, England
关键词
Inflammatory Bowel Disease (IBD); Dysplasia; Colonic adenoma; Interleukin; 6; STAT3; SOCS3; INFLAMMATORY-BOWEL-DISEASE; STAT3; ACTIVATION; EPITHELIAL-CELLS; IL-6; CANCER; INTERLEUKIN-6; EXPRESSION; SURVEILLANCE; SURVIVAL; GROWTH;
D O I
10.1016/j.prp.2020.153211
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: IL6-IL6R-STAT3-SOCS3 signaling pathway is known to play important roles in regulating intestinal epithelial homeostasis, in pathogenesis of inflammatory bowel disease (IBD), and in tumorigenesis of colorectal neoplasia. We studied the expressions of these factors in IBD-associated dysplasia and compared to sporadic colorectal adenomas in non-IBD individuals. Materials and methods: The expression of IL6, IL6R, STAT3, and SOCS3 within dysplastic as well as background non-dysplastic epithelial cells was evaluated by immunohistochemistry in 26 sporadic colorectal adenomas in non-IBD patients, 32 adenoma-like and 30 non-adenoma-like dysplastic lesions in IBD (41 ulcerative colitis, 21 Crohn's disease) patients. The level of expression of each factor was arbitrarily scored as 0, 1, 2, and 3. Results: In both IBD and non-IBD lesions, neoplastic epithelium showed a higher expression of all factors, except the IL6R, as compared to non-neoplastic epithelium. For non-neoplastic epithelium between IBD and non-IBD settings, the colitic epithelium showed a similar IL6, lower IL6R, higher STAT3, and higher SOCS3 expression. As compared to non-IBD adenomas, IBD-associated dysplasia showed a significantly lower IL6, lower IL6R, higher STAT3, and lower SOCS3 expression. Most notably, a parallel-elevation pattern of STAT3/SOCS3 ex-pressions was seen in non-IBD adenomas but an inverse-expression pattern of STAT3/SOCS3 seen in IBD dysplastic lesions. No significant differences existed between adenoma-like and non-adenoma-like lesions. Conclusions: IL6/IL6R-STAT3-SOCS3 signaling pathway does not seem to be preferentially associated with IBDassociated dysplasia. However, the STAT3-SOCS3 interaction appears dysregulated in IBD, characterized by a loss of STAT3/SOCS3 balance,i.e., loss of the normal negative regulation of SOCS3.
引用
收藏
页数:6
相关论文
共 32 条
  • [1] Analysis of the IL-6/STAT3 signalling pathway and DNA methylation patterns in patients with IBD
    Ali, Raja Affendi Raja
    Hartnett, Lori
    Geeleher, Paul
    Seoighe, Cathal
    Golden, Aaron
    Egan, Laurence
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 146 - 146
  • [2] Natural small molecule bigelovin suppresses orthotopic colorectal tumor growth and inhibits colorectal cancer metastasis via IL6/STAT3 pathway
    Li, Mingyue
    Yue, Grace Gar-Lee
    Song, Li-Hua
    Huang, Mao-Bo
    Lee, Julia Kin-Ming
    Tsui, Stephen Kwok-Wing
    Fung, Kwok-Pui
    Tan, Ning-Hua
    Lau, Clara Bik-San
    BIOCHEMICAL PHARMACOLOGY, 2018, 150 : 189 - 199
  • [3] Mesenchymal stem cells inhibit alveolar macrophages from polarization to inflammatory phenotype through the IL6/STAT3/SOCS3 signaling pathway
    Zhang, Hangjie
    Ye, Fei
    Zong, Chen
    Jing, Yingying
    Yang, Xue
    Lai, Fobao
    Dong, Yulong
    Pan, Xiaorong
    Zhu, Jingni
    Li, Xiaoyong
    Liang, Lei
    Hou, Xiaojuan
    Wei, Lixin
    Han, Zhipeng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 13418 - 13432
  • [4] miRNA-320 inhibits colitis-associated colorectal cancer by regulating the IL-6R/STAT3 pathway in mice
    Wu, Meng-Yao
    Luo, Yu-Xin
    Jia, Wen-Xiu
    Wang, Dan-Dan
    Sun, Dong-Lei
    Song, Jia
    Wang, Jing
    Niu, Wei-Wei
    Zhang, Xiao-Lan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (02) : 695 - +
  • [5] Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway
    Tian, Yun
    Ye, Ying
    Gao, Wei
    Chen, Hong
    Song, Ting
    Wang, Daqing
    Mao, Xiaoyun
    Ren, Changshan
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2011, 26 (01) : 13 - 22
  • [6] Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
    Yang, Jie
    Qian, Shihui
    Cai, Xueting
    Lu, Wuguang
    Hu, Chunping
    Sun, Xiaoyan
    Yang, Yang
    Yu, Qiang
    Gao, S. Paul
    Cao, Peng
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (06) : 1190 - 1200
  • [7] Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling
    Xiaohong Ye
    Hua Wu
    Luoyan Sheng
    Yi-xin Liu
    Fang Ye
    Mo Wang
    Hu Zhou
    Ying Su
    Xiao-kun Zhang
    Nature Communications, 10
  • [8] Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling
    Ye, Xiaohong
    Wu, Hua
    Sheng, Luoyan
    Liu, Yi-xin
    Ye, Fang
    Wang, Mo
    Zhou, Hu
    Su, Ying
    Zhang, Xiao-kun
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [9] Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6–STAT3 signaling pathway
    Yun Tian
    Ying Ye
    Wei Gao
    Hong Chen
    Ting Song
    Daqing Wang
    Xiaoyun Mao
    Changshan Ren
    International Journal of Colorectal Disease, 2011, 26 : 13 - 22
  • [10] Curcuminoids Modulated the IL-6/JAK/STAT3 Signaling Pathway in LoVo and HT-29 Colorectal Cancer Cells
    Li, Qian
    Ding, Yanting
    Ou, Ying
    Li, Manjing
    Jithavech, Ponsiree
    Buranasudja, Visarut
    Sritularak, Boonchoo
    Xu, Yichun
    Rojsitthisak, Pornchai
    Han, Junsong
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (36) : 2867 - 2876